Atox Bio is a late stage clinical biotechnology company that develops novel immune modulators for critically ill patients with severe infections. Atox Bio has an ongoing contract No. HHSO100201400013 with the Biomedical Advanced Research and Development Authority (BARDA) supporting the development of Reltecimod in NSTI. The Company was established by Prof. Raymond Kaempfer and Dr. Gila Arad from the Hebrew University of Jerusalem and Yissum.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/04/17 | $30,000,000 |
Adams Street Partners Arix Bioscience  Asahi Kasei Integra Holdings Lundbeckfond Ventures OrbiMed Advisors SR One | undisclosed |
